Qureight Raises $20M Series B for AI Medical Imaging Platform

Qureight, an AI-powered imaging platform focused on clinical trials, has successfully secured $20 million in Series B funding. The investment, reported on 2026-07-29 by Tech.eu, will facilitate the expansion of its enterprise-grade imaging capabilities and precision endpoints, particularly for lung and heart diseases. This funding round underscores the growing importance of artificial intelligence in accelerating clinical research and advancing precision medicine.

The platform specialises in processing complex medical imaging data, offering tools that streamline the assessment of disease progression and treatment efficacy in clinical studies. By leveraging AI, Qureight aims to enhance the accuracy and speed of data analysis, providing critical insights for drug development. This focus on AI-driven diagnostics aligns with broader trends in healthcare technology, where AI is increasingly seen as a transformative force.

Prior efforts in this domain include projects like AI4CMR, which is developing AI-based clinical software for fully automated Cardiac Magnetic Resonance reporting. This initiative, funded under HORIZON, aims to simplify and accelerate the assessment of heart function and structure, unlocking the potential of magnetic resonance as a routine imaging tool for cardiovascular disease. Another HORIZON-funded project, AIMIX, explores inclusive AI for accessible medical imaging across resource-limited settings, highlighting the diverse applications of AI in radiology.

The significant capital injection into Qureight reflects investor confidence in AI's potential to revolutionise clinical trial processes and improve patient outcomes. The company's specialisation in lung and heart diseases addresses critical areas of medical need, where precise and efficient diagnostic tools can have a profound impact. The funding will likely enable Qureight to scale its operations, broaden its technological offerings, and potentially enter new therapeutic areas.

What this means: This investment signals continued strong market validation for AI platforms that can accelerate clinical research. It points to a future where AI-driven imaging is integral to developing new treatments, especially for complex conditions like lung and heart diseases, by providing more efficient and precise data analysis in clinical trials.